Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (1044)	6/15/2005 5:05:35 PM
From: zeta1961	Read Replies (2) \| Respond to of 3722

ALTH..Ray and Bernard..do you follow this one?.. Been in a fairly tight range for quite a while..lead product(RSR-13) has generic name but I'm sure to make a typo-g- in P3 trials for brain mets in breast cancer patients..estimated interim look is Q1-2, 06..got denied approval last year because it was considered subset analysis of trial with both lung and breast cancer patients..I was very bullish getting it approved eventhough the actual breast cancer trial # was under 100..currently no position.. of note, Warburg/Pincus took a high stake in May(41%)..the YMB folk(some of them have owned and followed it for years) are thinking perhaps W/P plan to take a majority holding and sell the company off..timing unknown..this recent development piques my interest to buy some,...